Shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) traded up 5.6% on Wednesday . The stock traded as high as $8.25 and last traded at $8.13, with a volume of 130,112 shares trading hands. The stock had previously closed at $7.70.

Several analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a research note on Wednesday, July 6th. Bank of America Corp. cut shares of Tandem Diabetes Care from a “neutral” rating to an “underperform” rating in a research note on Thursday, March 24th. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, June 15th. Sterne Agee CRT reissued a “neutral” rating on shares of Tandem Diabetes Care in a research note on Monday, May 16th. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $12.00 price target on shares of Tandem Diabetes Care in a research note on Thursday, April 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $14.21.

The company’s market capitalization is $251.00 million. The firm has a 50-day moving average price of $7.42 and a 200-day moving average price of $8.33.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, April 28th. The medical device company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. During the same period in the previous year, the firm posted ($0.83) earnings per share. The firm had revenue of $20.06 million for the quarter, compared to analyst estimates of $17.67 million. The company’s revenue for the quarter was up 63.0% on a year-over-year basis. Equities analysts expect that Tandem Diabetes Care Inc. will post ($2.16) earnings per share for the current fiscal year.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.